SCHEMBL1177526

SCHEMBL1177526

CCc1ccccc1C1COCCN1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 1/20 0.36
BAZ2A Q9UIF9 1/20 0.35
HCRTR2 O43614 1/20 0.35
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34
CTSK P43235 1/20 0.33
SLC6A2 P23975 3/20 0.32
CYP2D6 P10635 2/20 0.32
SLC6A4 P31645 1/20 0.32
ADRA1A P35348 1/20 0.32
HTR2B P41595 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MAPK1 P28482 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29748038 0.79 HTR2C (0.43) PRKACAPRKACGPRKACBSLC6A2ADRA1A
SCHEMBL11138422 0.79 HTR2C (0.43) PRKACAPRKACGPRKACBSLC6A2ADRA1A
SCHEMBL14434903 0.76 HCRTR2 (0.38) CTSBHCRTR2SLC6A2CYP2D6SLC6A4
SCHEMBL13896906 0.76 HCRTR2 (0.38) CTSBHCRTR2SLC6A2CYP2D6SLC6A4
SCHEMBL28909603 0.76 HCRTR2 (0.47) HCRTR2MEN1KMT2A
SCHEMBL28540055 0.76 HCRTR2 (0.47) HCRTR2MEN1KMT2A
SCHEMBL20170480 0.76 HCRTR2 (0.47) HCRTR2MEN1KMT2A
SCHEMBL23136984 0.76 PRKACA (0.45) PRKACAPRKACGPRKACBSLC6A2ADRA1A
SCHEMBL24005407 0.76 PRKACA (0.36) PRKACAPRKACGPRKACBSLC6A2SLC6A4
SCHEMBL5054635 0.76 HTR2A (0.37) PRKACAPRKACGPRKACBHTR2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881827-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-09-28 EP disclosed
US-7888344-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2011-02-15 US disclosed
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2008-12-11 US disclosed
EP-1881827-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2008-01-30 EP disclosed
WO-2006114606-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors MAP4K2, PDPK1, DAPK2 CTSB 2911/4885BAZ2A 1342/4885HCRTR2 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.